In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654

O Barret, D Thomae, A Tavares, D Alagille… - Journal of Nuclear …, 2014 - Soc Nuclear Med
Phosphodiesterase (PDE) 10A is an enzyme involved in the regulation of cyclic adenosine
monophosphate and cyclic guanosine monophosphate and is highly expressed in medium …

Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain

S Celen, M Koole, M De Angelis, I Sannen… - Journal of nuclear …, 2010 - Soc Nuclear Med
Phosphodiesterases are enzymes that inactivate the intracellular second messengers 3′,
5′-cyclic adenosine-monophosphate and/or cyclic guanosine-monophosphate. Of all 11 …

Preclinical evaluation of a promising C-11 labeled PET tracer for imaging phosphodiesterase 10A in the brain of living subject

H Liu, H Jin, X Yue, X Zhang, H Yang, J Li, H Flores… - Neuroimage, 2015 - Elsevier
Abstract Phosphodiesterase 10A (PDE10A) plays a key role in the regulation of brain striatal
signaling. A PET tracer for PDE10A may serve as a tool to evaluate PDE10A expression in …

Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging

K Van Laere, RU Ahmad, H Hudyana, S Celen… - European journal of …, 2013 - Springer
Abstract Purpose Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP-hydrolysing enzyme
with a central role in striatal signalling and implicated in neuropsychiatric disorders such as …

Discovery and development of 11C-Lu AE92686 as a radioligand for PET imaging of phosphodiesterase10A in the brain

J Kehler, JP Kilburn, S Estrada… - Journal of Nuclear …, 2014 - Soc Nuclear Med
Phosphodiesterase 10A (PDE10A) plays a key role in the regulation of brain striatal
signaling, and several pharmaceutical companies currently investigate PDE10A inhibitors in …

First-in-human assessment of the novel PDE2A PET radiotracer 18F-PF-05270430

M Naganawa, RN Waterhouse, N Nabulsi… - Journal of Nuclear …, 2016 - Soc Nuclear Med
This was a first-in-human study of the novel phosphodiesterase-2A (PDE2A) PET ligand 18F-
PF-05270430. The primary goals were to determine the appropriate tracer kinetic model to …

Evaluation of a novel PDE10A PET radioligand, [11C]T‐773, in nonhuman primates: Brain and whole body PET and brain autoradiography

A Takano, V Stepanov, B Gulyás, R Nakao, N Amini… - Synapse, 2015 - Wiley Online Library
ABSTRACT Phosphodiesterase 10A (PDE10A) is considered to be a key target for the
treatment of several neuropsychiatric diseases. The characteristics of [11C] T‐773, a novel …

Initial characterization of a PDE10A selective positron emission tomography tracer [11C] AMG 7980 in non-human primates

DR Hwang, E Hu, S Rumfelt, B Easwaramoorthy… - Nuclear Medicine and …, 2014 - Elsevier
Abstract Introduction Phosphodiesterase 10A (PDE10A) is an intracellular enzyme
responsible for the breakdown of cyclic nucleotides which are important secondary …

Preclinical evaluation of 18F-PF-05270430, a novel PET radioligand for the phosphodiesterase 2A enzyme

L Chen, N Nabulsi, M Naganawa… - Journal of Nuclear …, 2016 - Soc Nuclear Med
The enzyme phosphodiesterase 2A (PF-05270430) is a potential target for development of
novel therapeutic agents for the treatment of cognitive impairments. The goal of the present …

Synthesis and preclinical evaluation of an 18F labeled PDE7 inhibitor for PET neuroimaging

D Thomae, S Servaes, N Vazquez… - Nuclear Medicine and …, 2015 - Elsevier
Abstract Introduction Phosphodiesterase 7 (PDE7) hydrolyzes selectively cyclic adenosine
monophosphate (cAMP) which is an intracellular second messenger. PDE7 is expressed by …